Urol. praxi. 2019;20(1):9-12 | DOI: 10.36290/uro.2019.040

Use of botulinum toxin in paediatric urology

MUDr. Pavel Zerhau, CSc., MUDr. Matej Husár
Urologické oddělení KDCHOT FN Brno

Lower urinary tract dysfunction in children is very often connected with reduced compliance and urinary bladder hyperactivity.
The treatment is conservative, moreover surgical in extreme cases. Endoscopic intravesical botulinum toxin application as miniinvasive
therapy occur among them. It represents safe and efficient treatment leading to continence increase, lower occurrence
of uninhibited contraction and urodynamic status improvement.

Keywords: urinary tract dysfunction, detrusor hyperactivity, intravesical application, botulinum toxin A

Published: March 18, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zerhau P, Husár M. Use of botulinum toxin in paediatric urology. Urol. praxi. 2019;20(1):9-12. doi: 10.36290/uro.2019.040.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bauer SB. Initial management of meningomyelocele children. In: Corcos J, Ginsberg D, Karsenty G. Textbook of the neurogenic bladder, 3th ed.,CRC Press, Taylor et Francis Group, Boca Raton, London, New York 2016: 633-644. Go to original source...
    2. Dítě Z, Kočvara R. Intravezikální instilace propiverinu v léčbě neurogenních dysfunkcí močového měchýře. Urol. praxi, 2012; 13(6): 264-266.
    3. Krhut J. Aplikace botulotoxinu u OAB. In: Hyperaktivní močový měchýř. Maxdorf, Praha, 2007: 95-97.
    4. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, et al. Decreased sensory receptors P2X3 and TRPV1 in suburotelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174(3): 977-982. Go to original source... Go to PubMed...
    5. Aoki KR. Pharmacology and imunology of botulinum toxin type A serotypes. Clin Dermatos, 2003; 21: 476-480. Go to original source... Go to PubMed...
    6. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophtalmol Soc 1981; 79: 73-770.
    7. Jeffery S, Fynes M, Lee F, Wang K, et al. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int. 2007; 100(6): 1302-1306. Go to original source... Go to PubMed...
    8. Krhut J, Mainer K, Kopecký J. Botulotoxin A - alternativa v léčbě hyperaktivního měchýře. Čes Urol 2004; (2): 19-21.
    9. Krhut J, Zachoval R, Hradílek P, Havránek O, Zapletalová O. Botulotoxin v léčbě detruzorové hyperaktivity u pacientek s roztroušenou sklerózou. Cesk Slov Neurol N 2008; 104(71): 429-434.
    10. Tiryaki S, Yagmur I, Parlar Y, Ozel K, Akyildiz C, Avanoglu A, Ulman I. Botulinum injection is useless on fibrotic neuropathic bladders. J Pediatr Urol 2015; 11(1): 27. Go to original source... Go to PubMed...
    11. Zerhau P. Endoskopická léčba hyperaktivity detruzoru močového měchýře u dětí botulotoxinem A. Závěrečná zpráva grantu IGA, Brno 2011: 39 s.
    12. Marte A. Onabotulinumtoxin A for treating overactive/poor compliant bladders in children and adolescents with neurogenic bladder secondary to myelomeningocele. Toxins (Basel) 2012; 28; 5(1): 16-24. Go to original source... Go to PubMed...
    13. Šámal V. Léčba neurogenní hyperaktivity detruzoru botulinumtoxinem A - první zkušenosti se subslizniční aplikací. Ces Urol 2011; 15(2): 108-112.
    14. Bottet F, et al. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed. Neurourol Urodyn 2018; 37(1): 291-297. Go to original source... Go to PubMed...
    15. Peyronnet B, et al. Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity. World J Urol 2016; 34(5): 755-761. Go to original source... Go to PubMed...
    16. Peyronnet B, et al. Intradetrusor injections of onabotulinum toxin A (Botox(R)) 300 U or 200 U versus abobotulinum toxin A (Dysport(R)) 750 U in the management of neurogenic detrusor overactivity: A case control study. Neurourol Urodyn 2017; 36(3): 734-739. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.